Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1

Status

Completed 5

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5NET 2Genitourinary 1Dermatologic 1

Conditions

Neoplasms 805Carcinoma, Non-Small-Cell Lung 767Breast Neoplasms 731Neoplasm Metastasis 340Colorectal Neoplasms 339Prostatic Neoplasms 324Multiple Myeloma 309Melanoma 305Recurrence 237Ovarian Neoplasms 236Leukemia, Myeloid, Acute 236Lymphoma, Non-Hodgkin 213Lung Neoplasms 211Carcinoma, Renal Cell 200Lymphoma 189Lymphoma, Follicular 163Pancreatic Neoplasms 157Leukemia, Lymphocytic, Chronic, B-Cell 149Carcinoma, Hepatocellular 140Stomach Neoplasms 137Leukemia 133Head and Neck Neoplasms 128Lymphoma, Large B-Cell, Diffuse 126Parkinson Disease 4, Autosomal Dominant Lewy Body 119Squamous Cell Carcinoma of Head and Neck 110Urinary Bladder Neoplasms 109Carcinoma 101Small Cell Lung Carcinoma 99Triple Negative Breast Neoplasms 97Glioblastoma 96

Interventions

pasireotide 4Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Acromegaly × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Novartis

Phase 3 Completed
123 enrolled 27 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Novartis

Phase 2 Completed
33 enrolled 24 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01137682 2018-04-05

PAOLA

Novartis

Phase 3 Completed
198 enrolled 17 charts
Endocrine

Acromegaly, Pituitary Neoplasms

NCT02299089 2017-12-15

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Camurus AB

Phase 2 Completed
12 enrolled 18 charts
EndocrineNET

Acromegaly, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡